The St. Jude experience.
This paper covers our experience with the use of the St. Jude prosthetic heart valve from November 1979 through August 1983 in 91 patients operated on for aortic and mitral valve replacement. Nonfatal complications included hemorrhagic sequela due to anticoagulation, with an annual rate of 1 percent (1.4 percent per 100 patient years), thromboembolism with an annual rate of 0.8 percent (0.87 percent per 100 patient years), sternal infection 1 percent, operative cardiovascular accident 1 percent, and pericardial tamponade 1 percent. Operative mortality was 1 percent, early mortality (within 30 days) was 3 percent, and late mortality was 3 percent, with a total overall mortality of 7 percent. Excluding two patients who died from noncardiac causes, the overall mortality was 5 percent. The mortality rate per year was 2 percent. The survival rate 3.8 years postoperatively was 89 percent for mitral valve replacement patients and 93 percent for aortic valve replacement patients, for an overall 38 year survival rate of 92 percent. All patients were anticoagulated with warfarin. There were no instances of valve failure, replacement, or serious hemolysis. Eighty-three percent were active or working with a New York heart functional class I. In our experience, the complication rate with the St. Jude valve is as low or lower than that for any other mechanical prosthetic cardiac valve available in the world today.